Shire news

01 Sep 2010 Elections for Interim Dividend in Respect of the Six Months to June 30, 2010
01 Sep 2010 Total Voting Rights
31 Aug 2010 Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
26 Aug 2010 Shire Announces European Approval of VPRIV® (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
26 Aug 2010 Notification of major interests in shares (28KB PDF)
24 Aug 2010 Pentasa® - Shire Receives Ruling From FDA on Citizen’s Petition
20 Aug 2010 Correction - Director/PDMR Shareholding
17 Aug 2010 Statement re ProAmatine
17 Aug 2010 Director/PDMR Shareholding
11 Aug 2010 Half Yearly Report
10 Aug 2010 Shire agrees to divest Daytrana® (methylphenidate transdermal system) CII to Noven Pharmaceuticals, Inc.; Shire’s 2010 earnings outlook unchanged
05 Aug 2010 Director/PDMR Shareholding
05 Aug 2010 Published Study Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Provided Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
04 Aug 2010 Study Published in the New England Journal of Medicine Demonstrates Efficacy and Favourable Safety Profile of Firazyr® (Icatibant) for the Treatment of Hereditary Angioedema (HAE) Attacks
04 Aug 2010 Shire delivers excellent Q2 performance with total revenues up 35%. Full year earnings expectations raised.
03 Aug 2010 Shire Proposes to Expand Specialist Gastrointestinal Portfolio
02 Aug 2010 Shire Appoints Gráinne Higgins Global Vice President of Human Resources for Human Genetic Therapies Business
02 Aug 2010 Total Voting Rights
20 Jul 2010 Nonsafety voluntary recall and withdrawal of a limited portion of Daytrana® (methylphenidate transdermal system) patches (83KB PDF)
15 Jul 2010 Second quarter 2010 results date notification – August 4, 2010
08 Jul 2010 Lialda® - Shire Files Suit against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
06 Jul 2010 FDA Approves Daytrana® (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents
01 Jul 2010 Total Voting Rights
01 Jul 2010 Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV® (velaglucerase alfa) through 69 months
30 Jun 2010 Shire Purchases Strategic Site in Massachusetts
28 Jun 2010 Shire named Company of the Year at Mediscience Awards
25 Jun 2010 Shire Receives CHMP Positive Opinion for VPRIV™ (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
21 Jun 2010 Director/PDMR Shareholding
17 Jun 2010 Two New Board Directors Appointed
28 May 2010 Shire Receives LIALDA® Paragraph IV Notice Letter from Zydus Pharmaceuticals
25 May 2010 Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
19 May 2010 Shire Receives 2010 Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for injection)
04 May 2010 Total Voting Rights
04 May 2010 FDA Approves Labeling Change for Vyvanse® (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD1
29 Apr 2010 Shire's replenished portfolio drives excellent quarterly performance
27 Apr 2010 Results of the Annual General Meeting held on April 27, 2010 (19KB PDF)
20 Apr 2010 First quarter 2010 results date notification – April 29, 2010
01 Apr 2010 Total Voting Rights
01 Apr 2010 Director/PDMR Shareholding
01 Apr 2010 Annual Information Update
25 Mar 2010 Annual Report and Accounts
25 Mar 2010 Shire Presents Positive Data for Patients with Type 1 Gaucher Disease Who Switched to VPRIVTM
18 Mar 2010 Director/PDMR Shareholding
15 Mar 2010 New Board Director Appointed
11 Mar 2010 Director/PDMR Shareholding
09 Mar 2010 Director/PDMR Shareholding
05 Mar 2010 Director/PDMR Shareholding
04 Mar 2010 District Court Upholds FDA’s Grant of 5-Year Market Exclusivity to VYVANSE®
03 Mar 2010 Director/PDMR Shareholding
03 Mar 2010 Director/PDMR Shareholding
02 Mar 2010 Supplementary Reporting Announcement
01 Mar 2010 Elections for Interim Dividend in Respect of the Six Months to December 31, 2009
01 Mar 2010 Total Voting Rights
01 Mar 2010 March is Kidney Health Month
01 Mar 2010 Mars est le mois de la santé rénale
26 Feb 2010 Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
26 Feb 2010 FDA Press Release - FDA Approves Therapy to Treat Gaucher Disease
26 Feb 2010 Shire Supports Rare Disease Day 2010
24 Feb 2010 Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA)
19 Feb 2010 Excellent results in a transformational year for Shire; core product sales up 25%
11 Feb 2010 Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naïve Patients with Type 1 Gaucher Disease
04 Feb 2010 Full Year 2009 results date notification – 19 February 2010
03 Feb 2010 Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lysosomal Disease Network (LDN) World Symposium
01 Feb 2010 VYVANSE® — new ADHD treatment option — now available in Canada
01 Feb 2010 Total Voting Rights
26 Jan 2010 Notification of major interests in shares
18 Jan 2010 Directorate Change
04 Jan 2010 Total Voting Rights

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device.

Related links

Our strategy
Corporate Governance
Media